



To: The Romanian Financial Supervisory Authority
Financial Instruments and Investments Sector
The Bucharest Stock Exchange
Regulated Spot Market, Category Standard (Shares)

From: ZENTIVA S.A.

CURRENT REPORT

pursuant to art. 122 para. (1) of Law no. 24/2017 on issuers of financial instruments and market operations, as amended, as well as pursuant to art. 234 para. (1) letter i) of the Financial Supervisory Authority Regulation no. 5/2018 on issuers of financial instruments and market operations

Report date: 16 November 2020

Name of the issuing entity: ZENTIVA S.A. (the “Company”)

Registered office: 50 Theodor Pallady Blvd.
3rd District, Bucharest
Romania

Phone/Fax number: +4021.304.72.00/ +4021.345.40.04

Webpage: www.zentiva.ro

Registration number with the Bucharest Trade Register and sole registration code: J40/363/1991
336206

Share Capital: RON 69,701,704

Number of shares: 697,017,040 shares

Regulated market on which the issued securities are traded: Bucharest Stock Exchange, Main Segment, Category Standard (Shares)

Important events to be reported: The conclusion of an agreement with a value that is estimated to exceed 10% of the turnover achieved in 2019, according to the annual financial statements

Considering the provisions of the art. 122 para. (1) of Law no. 24/2017 on issuers of financial instruments and market operations, as amended, as well as article 234 para. (1) letter i) of the FSA Regulation 5/2018 on issuers of financial instruments and market operations,

the Company would like to inform its shareholders and investors that on 16 November 2020 has signed with Biotehnos S.A. Addendum no. 3 to the Manufacturing and Supply Agreement dated 15.01.2009 (the “Agreement”), which has as subject matter the manufacture and supply of certain pharmaceutical



products by the Company, as manufacturer, to Biotehnos S.A., as beneficiary. Thus, the validity of the Agreement was extended and new commercial conditions were established between the parties.

By signing this Addendum, although the value of the Agreement cannot be determined accurately at this time, the Company estimates that the total value of the Agreement will exceed 10% of the net turnover reflected in the last annual financial statements (*i.e.*, as of 31 December 2019).

Simona Cocos

General Manager